Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
07 nov. 2019 08h30 HE
|
Predictive Oncology
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian...
Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
06 nov. 2019 08h30 HE
|
Predictive Oncology
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted...
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
05 nov. 2019 08h00 HE
|
Celsion CORP
GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
29 oct. 2019 19h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22 oct. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
30 sept. 2019 14h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
27 sept. 2019 10h15 HE
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
28 août 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 16h05 HE
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
31 juil. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...